[2,3-diphosphoglycerate level during the active and maintenance treatment of iron-deficiency anemia patients].
The objective of the present study was to obtain information about the duration of tissue hypoxia in patients with iron deficiency anemia. That fact is of importance for the determination of the duration of maintenance iron therapy. The level of 2,3-diphosphoglycerate was studied during the treatment, after the correction of anemic syndrome and after 60-day out-patient department treatment. The data obtained revealed that the level of 2,3-diphosphoglycerate was considerably elevated, as compared with the norm, before the treatment. After the active treatment and correction of anemic syndrome it was decreased, but remaining above the norm. By the 60th day of the out-patient department treatment the decrease continued and the level of 2,3-diphosphoglycerate approached the norm.
D019794:2,3-Diphosphoglycerate; D000293:Adolescent; D000328:Adult; D000747:Anemia, Hypochromic / Q000097:blood* / Q000188:drug therapy; D004163:Diphosphoglyceric Acids / Q000097:blood*; D004359:Drug Therapy, Combination; D005260:Female; D005296:Ferrous Compounds / Q000627:therapeutic use; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007501:Iron / Q000097:blood; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D004163:Diphosphoglyceric Acids; D005296:Ferrous Compounds; D006454:Hemoglobins; D019794:2,3-Diphosphoglycerate; D007501:Iron; C031621:ferrous fumarate
Nivo na 2,3-difosfoglitserata po vreme na aktivno i poddŭrzhashto lechenie na bolni ot zheliazodefitsitna anemiia.